ICU Medical, Inc. — Q3 2014 Form 10-Q
Reporting period: Three and nine months ended September 30, 2014. ICU Medical develops, manufactures, and sells medical devices for infusion therapy, critical care, and oncology. Figures below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Financial performance
| Metric | Q3 2014 | Q3 2013 | First 9 months 2014 | First 9 months 2013 |
|---|---|---|---|---|
| Total revenue | $77.5 | $82.8 | $229.4 | $235.8 |
| Gross profit | $38.1 | $41.0 | $111.7 | $115.8 |
| Gross margin | 49.2% | 49.4% | 48.7% | 49.1% |
| Operating income | $8.4 | $15.4 | $27.0 | $38.4 |
| Net income | $6.4 | $11.0 | $19.0 | $27.1 |
| Diluted EPS | $0.42 | $0.72 | $1.22 | $1.79 |
| Cash provided by operations | Not provided for quarter | Not provided for quarter | $48.3 | $42.2 |
- Q3 sales declined about 6% year over year. By segment, infusion therapy sales fell 6%, critical care fell 10%, and oncology fell 5%. For the first nine months, infusion therapy fell 4%, critical care increased 1%, and oncology increased 1%.
- Operating income and net income fell materially in both comparison periods. R&D expense rose to $5.1 million in Q3 and $13.3 million year to date; Q3 also included $2.8 million of restructuring charges.
- Gross margin was broadly stable in Q3 and lower year to date. Management attributed the year-to-date decline to product mix and temporary product-line rework, partly offset by lower logistics costs.
- Net cash from operations increased year to date despite lower net income, supported in part by a $9.4 million reduction in accounts receivable. Inventory increased $4.7 million.
Liquidity, capital resources, and balance sheet
- At September 30, 2014, cash and cash equivalents were $252.2 million and investment securities were $77.5 million, totaling $329.7 million, up $32.8 million from year-end 2013.
- Total current assets were $424.5 million and current liabilities $29.3 million. The balance sheet reports no borrowings or other debt; total liabilities shown were $36.3 million, including deferred taxes and income tax liability.
- Year-to-date investing cash outflow was $25.2 million, including $14.9 million of property and equipment purchases. Financing cash inflow was $8.5 million, including stock-option and employee stock-plan proceeds, offset partly by treasury-stock purchases.
- Management estimated 2014 capital expenditures of $16–19 million and said existing cash, investments, and expected operating cash flow should fund operations for the next 12 months. The Salt Lake City plant expansion was completed in June 2014.
- The company had $19.3 million of cash at foreign subsidiaries. Investment securities were described as investment grade; the filing states all are callable within one year.
Material changes, outlook, and risks
- Q3 restructuring reduced the workforce by 61 employees and reorganized selling and corporate infrastructure. The $2.8 million charge included termination and related costs; $2.1 million remained accrued at September 30, with most expected to be paid in Q4 2014 and Q1 2015.
- Hospira accounted for 37% of Q3 revenue and 36% of year-to-date revenue; it represented 30% of accounts receivable at quarter-end. Lower Hospira infusion sales were a principal cause of the year-to-date sales decline. The customer agreements extend through most of 2018, subject to their terms.
- Management gave no specific revenue or earnings forecast. It described continued investment in product development, sales, and marketing, and pursuit of new products, acquisitions, and purchasing-network opportunities; success is not assured.
- Key risks include reliance on Hospira and a small number of customers, competition and price pressure, customer ordering variability, successful development and commercialization of new products, international and foreign-exchange exposure, raw-material costs, and regulatory, litigation, and intellectual-property risks. The company did not hedge foreign-currency exposure; management estimated a 10% euro conversion change would affect specified net balance-sheet assets by about $8.9 million.
- Routine legal proceedings were not expected by management to have a material adverse effect. Indemnification commitments have no stated maximum, although the company said it had not incurred and did not expect material liability. No material changes to previously disclosed risk factors were reported.
- Year-to-date foreign-currency translation losses were $7.7 million, contributing to accumulated other comprehensive loss of $5.5 million at quarter-end.
Important facts for investors to verify
- Whether Hospira sales, contract terms, or purchasing patterns change, given the customer’s large share of revenue and receivables.
- Whether revenue and operating margins stabilize, particularly in domestic infusion therapy, and whether product-line rework or unfavorable mix continues.
- Whether increased R&D spending and newer products, including ChemoLock, generate sustained sales and returns.
- Actual restructuring cash payments and 2014 capital expenditures compared with management’s estimates.
- Changes in foreign-exchange exposure, investment liquidity and value, and the company’s ability to maintain liquidity under a more severe downturn.